Tdap vaccine

Tdap-Swedish Institute for Infectious Disease Control-tetanus-diphtheria-pertussis refers to the Tdap (tetanus, reduced-dose diphtheria, and acellular pertussis) booster vaccines evaluated by the Swedish Institute for Infectious Disease Control (SMI) in clinical trials, specifically as a school-leaving booster for adolescents. The primary vaccines studied in this context include Td5ap (COVAXiS), a five-component acellular pertussis vaccine, and Td1aP (diTekiBooster), a one-component acellular pertussis vaccine. These vaccines are designed to reinforce immunity against *Clostridium tetani*, *Corynebacterium diphtheriae*, and *Bordetella pertussis*. The mechanism of action involves the induction of neutralizing antibodies against tetanus and diphtheria toxins, as well as immune responses against pertussis antigens such as pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae. These vaccines are typically administered via intramuscular injection and are adsorbed onto aluminum salts to enhance immunogenicity.

Brand names

COVAXiSdiTekiBooster

Other names

Tdap-Swedish Institute for Infectious Disease Control-tetanus-diphtheria-pertussisTetanus-diphtheria-acellular pertussis vaccineTdap booster